<?xml version="1.0" encoding="UTF-8"?>
<p>Independent of the study design, the patient population that is being targeted for CCP use may be suboptimal. An enduring finding across studies of CP is the need for early intervention.
 <sup>
  <xref rid="B1" ref-type="bibr">1</xref>,
  <xref rid="B4" ref-type="bibr">4</xref>,
  <xref rid="B7" ref-type="bibr">7</xref>,
  <xref rid="B9" ref-type="bibr">9</xref>
 </sup> Yet, the overwhelming majority, if not all, CCP to date has been transfused to patients with advanced COVID-19. At inception, the US expanded access program required severe or life-threatening COVID-19 for enrollment.
 <sup>
  <xref rid="B6" ref-type="bibr">6</xref>
 </sup> Although the desire to help those who are most sick is intuitive, this is the population for which evidence of benefit from CP is weakest. Late intervention also fails to abrogate the societal burden of disease. In short, intervention likely needs to occur earlier in the disease process.
 <sup>
  <xref rid="B4" ref-type="bibr">4</xref>
 </sup>
</p>
